Skip to main content

Table 2 Baseline characteristics for patients with and without any osteoporotic fracture

From: The effect of homocysteine-lowering with B-vitamins on osteoporotic fractures in patients with cerebrovascular disease: substudy of VITATOPS, a randomised placebo-controlled trial

Baseline characteristic

 

With any fracture

Without fracture

p-value

(n = 145)

(n = 8019)

(log-rank test)

N (%)

N (%)

 

Sex

Male

55 (37.9)

5163 (64.4)

<.001

 

Female

90 (62.1)

2854 (35.6

 

Age

<65 yrs

23 (15.9)

4276 (53.3)

<.001

 

> = 65 yrs

122 (84.1)

3743 (46.7)

 

Ethnicity

Western European

105 (78.9)

3171 (42.3)

<.001

 

Oriental

15 (11.3)

1898 (24.7)

 
 

South Asian

7 (5.3)

2046 (26.6)

 
 

Other

6 (4.5)

566 (7.4)

 

Oxford Handicap Score

> = 3

35 (24.7)

1859 (23.8)

0.18

 

<3

107 (75.4)

5952 (76.2)

 

Smoking (ever)

Yes

72 (49.7)

3947 (49.9)

0.43

 

No

73 (50.3)

3966 (50.1)

 

Alcohol (any)

Yes

54 (37.2)

2269 (28.3)

0.20

 

No

91 (62.8)

5748 (71.7)

 

Diabetes

Yes

24 (16.6)

1875 (23.7)

0.21

 

No

121 (83.5)

6047 (76.3)

 

Stroke

Yes

28 (19.3)

1254 (15.8)

0.28

 

No

117 (80.7)

6664 (84.2)

 

Myocardial infarction

Yes

15 (10.3)

583 (7.4)

0.33

 

No

130 (89.7)

7317 (92.6)

 

Hypertension

Yes

105 (72.4)

5632 (71.1)

0.45

 

No

40 (27.6)

2285 (28.9)

 

Depression

Yes

16 (16.0)

528 (7.4)

0.003

 

No

84 (84.0)

6650 (92.6)

 

Antidepressant medication

Yes

24 (16.6)

536 (6.8)

<.001

 

No

121 (83.5)

7332 (93.2)

 

Corticosteroid medication

Yes

3 (2.1)

47 (0.6)

0.011

 

No

142 (97.9)

7972 (99.4)

 

Any Osteoporosis Medication *

Yes

23 (15.9)

556 (6.9)

<.001

 

No

122 (84.1)

7463 (93.1)

 

Homocysteine level at baseline †

 

(n = 40)

(n = 1165)

0.43

mean (SD)

14.2 (6.2)

14.3 (8.6)

  1. * Including Calcium, Vitamin D, Bisphosphonates and Hormone replacement therapy;
  2. † Not all participants had homocysteine levels measured at Baseline.